Top
DiscGenics Announces US Study of Cell Therapy for Disc Degeneration Clears Safety Review - Healing Genes
2821
post-template-default,single,single-post,postid-2821,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

DiscGenics Announces US Study of Cell Therapy for Disc Degeneration Clears Safety Review

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

DiscGenics has received the go-ahead from an independent data safety monitoring committee (DSMC) to enroll the final 24 patients in its first-in-human U.S. clinical study of IDCT, an allogeneic, injectable disc cell therapy for mild to moderate degenerative disc disease (DDD).

The DSMC completed a third and final planned mid-trial safety review following treatment of the first six subjects in the high dose study cohort, each of whom was treated based on random assignment into one of three arms: high dose IDCT study treatment, vehicle or placebo.

The DSMC reported there were no safety issues and recommended that the study proceed with completion of patient enrollment with no changes to the protocol.

This news closely follows a recent company announcement that the second planned safety review of the first 30-subject low dose study cohort revealed no safety issues.

Read the full story here: https://www.americanpharmaceuticalreview.com/1315-News/518999-DiscGenics-Announces-US-Study-of-Cell-Therapy-for-Disc-Degeneration-Clears-Safety-Review/

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader